Metraipolis › archive › dc_863d3fc0ceca

Post-marketing surveillance of quizartinib for relapsed or refractory FLT3-ITD-positive acute myeloid leukemia in Japan — Europe PMC PMID:41746494

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/41746494
DOI: 10.1007/s12185-[numero omesso]-7
License (as archived): solo-consultazione
Archived: 2026-11-05T11:28:04.427Z
SHA-256 of the archived text: 5c8a5b2a95ceedbd2975cd85baa28e48f616b2ad7804e6cf3b2fcbab05c168fb
Stable URL of this page: https://metraipolis.com/documento/dc_863d3fc0ceca

How to cite

Post-marketing surveillance of quizartinib for relapsed or refractory FLT3-ITD-positive acute myeloid leukemia in Japan — Europe PMC PMID:41746494 — Europe PMC (en), https://europepmc.org/article/MED/41746494 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_863d3fc0ceca (Metraipolis archive dc_863d3fc0ceca, sha256 5c8a5b2a95ceedbd2975cd85baa28e48f616b2ad7804e6cf3b2fcbab05c168fb)

BibTeX

@misc{dc863d3fc0ceca,
  title = {Post-marketing surveillance of quizartinib for relapsed or refractory FLT3-ITD-positive acute myeloid leukemia in Japan — Europe PMC PMID:41746494},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41746494},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_863d3fc0ceca; sha256 5c8a5b2a95ceedbd2975cd85baa28e48f616b2ad7804e6cf3b2fcbab05c168fb},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41746494. Agents can read the archived copy with the MCP tool read_document.